Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery

NCT03604861 · View on ClinicalTrials.gov ↗

Study Summary

The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine extended-release injection (RBP-6000). The study population will consist of participants from studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003). The RECOVER study will characterize OUD subjects' recovery process as they transition from the controlled clinical trial environment to the real world setting.

Interventions

  • OTHER Not applicable - no defined intervention

Study Locations (20)

Florida

  • Amit Vijapura — Jacksonville
  • Meridien Research — Lakeland
  • Try Research — Maitland
  • Innovative Clinical Research — Miami
  • Scientific Clinical Research — Miami
  • Research Centers of America — Oakland Park

California

  • Behavioral Research Specialists — Glendale
  • Collaborative Neuroscience Networks, Inc. — Long Beach
  • Synergy Research Center — National City
  • North County Clinical Research — Oceanside
  • Artemis Institute for Clinical Research — San Diego

Alabama

  • Winston Technology Research LLC — Haleyville
  • Boyett Health Services — Hamilton

Louisiana

  • Louisiana Research Associates — New Orleans
  • Louisiana Clinical Research — Shreveport

Massachusetts

  • Stanley Street Treatment and Resources — Fall River
  • Adams Clinical Trials — Watertown

Arkansas

  • Woodland International Research Group — Little Rock

Mississippi

  • Precise Research Centers, Inc. — Flowood

Missouri

  • St. Louis Clinical Trials — St Louis

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2015-08
Est. Completion 2019-03

Sponsor

Indivior

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03604861

The ClinicalTrials.gov registry entry for NCT03604861 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Opioid-use Disorder appearing as the primary indexed condition, and to 1 intervention — of which Not applicable - no defined intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03604861 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Florida, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03604861 about?

NCT03604861 is a clinical study titled "An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery". The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine extended-release injection (RBP-6000). The study population will consist of particip...

What is the current status of trial NCT03604861?

This trial is currently completed. The enrollment target is 534 participants. The study started on 2015-08. Estimated completion is 2019-03.

What conditions does trial NCT03604861 study?

This clinical trial studies the following conditions: Opioid-use Disorder, Opioid-related Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03604861?

The interventions under investigation include: Not applicable - no defined intervention (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03604861?

This trial is sponsored by Indivior, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03604861 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial